Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | NA |
| Strategy: | Protein and peptide vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | In progress |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
An open-label study to evaluate the safety and immunogenicity of 2 doses of 100 µg BG505 SOSIP.664 gp140 vaccine, adjuvanted, given to a population of adults in good general health who have received 3 doses of 300 µg BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted
Description
CAVD 920 (IAVI C110) is a Phase I open-label clinical trial to evaluate the safety and immunogenicity of a prime/boost regimen using 3 doses of BG505 SOSIP.GT1.1 gp140 vaccine followed by 2 doses of BG505 SOSIP.664 gp140 vaccine.
Sign in to see full information about this study and to download study data.
Products
Alum BG505 SOSIP.664 Tris-NaCl Diluent 3M-052-AFIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.